2[1]World Health Organization.Hepatitis B.World Health Organization Fact Sheet 204 dex.(Revised October 2000).WHO Web site.http://www.who.int/mediacentre/factsheets/fs204/en/in html 被引量：1
3[3]Marcellin P,Chang TT,Lim SG,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.N Engl J Med,2003,348:808-816 被引量：1
4[4]Zeng MD,Yao GB,Wang YZ,et al.One year results from a multicenter double-blind,placebo (PLA)-controlled 5 year study of adefovir dipivoxil (ADV) in Chinese patients with HBeAg-positive chronic hepatitis B (CHB).Hepatology,2004,40(Suppl 1):730A 被引量：1
5[5]Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.N Engl J Med,2003,348:800-807 被引量：1
6[6]Hadziyannis S,Tassopoulos N,Heathcote E J,et al.Long-term (96 weeks) adevofir dipivoxil in HBeAg-negative chronic hepatitis results in significant virological,biochemical and histological improvement.Hepatology,2003,38(Suppl 1):273A 被引量：1
7[7]Hadziyannis S,Tassopoulos N,Chang TT,et al.Three years study of adevofir dipivoxil demonstrated sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES).J Hepatol,2004,40(Suppl 1):17 被引量：1
8[8]Hadziyannis S,Tassopoulos N,Chang TT,et al.Adevofir dipivoxil demonstrated sustained efficacy in HBeAg-negative chronic hepatitis B (CHB) patients.J Hepatol,2005,42(Suppl 2):178 被引量：1
9[9]Hadziyannis S,Tassopoulos N,Heathcote EJ,et al.Two years results from a double-blind,randomized,placebo-controlled study of adevofir dipivoxil for presumed precore mutant chronic hepatitis B.J Hepatol,2003,38(Suppl 2):143 被引量：1
10[10]Schiff ER,Lai CL,Hadziyannis S,et al.Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre-and post-liver transplantation patients.Hepatology,2003,38:1419-1427 被引量：1
